By Clet Wandui Masiga, Conservation Biologist, Geneticist and Farm Entrepreneur
It costs $136 million to discover, develop and commercialize GMOs having any specific trait. This cost represents money spent on staff, equipment and laboratory supplies, and the regulatory testing and registration process. The time taken is about 13 years. Much of this time which is about 5.5 years is regulatory and registration.
Below is information I obtained at crop life website on October 201 (https://croplife.org/plant-biotechnology/regulatory-2/cost-of-bringing-a-biotech-crop-to-market/).
Each year, millions of farmers around the world plant biotech crops for higher yields, improved crop quality and the ability to use sustainable farming practices such as no-till. Getting these innovative new traits from the lab to their fields requires a tremendous investment – a new research survey reveals how it all adds up.
- The cost of discovery, development and authorization of a new plant biotechnology trait introduced between 2008 and 2012 is US$136 million.
- The time from the initiation of a discovery project to commercial launch is 13.1 years on average for all relevant crops.
- The time associated with registration and regulatory affairs is increasing from a mean of 3.7 years for an event introduced before 2002, to the current (2011) estimated 5.5 years.
- Regulatory science, registration and regulatory affairs account for the longest phase in product development, estimated at 36.7% of total time involved.
- The trend in the number of units (candidate genes, constructs or genetic events) being screened in order to develop one trait is increasing.
From discovering new genetic traits, field testing and meeting intense regulatory requirements that ensure environmental and human safety, the overall plant biotech R&D process is costly and time-consuming. To determine the relative cost and duration of this process, Phillips McDougall conducted a research survey based on information provided by six of the industry’s largest biotech crop developers – BASF, Bayer CropScience, Dow AgroSciences, DuPont/Pioneer Hi-Bred, Monsanto and Syngenta AG.
The September 2011 survey entitled, “The cost and time involved in the discovery, development and authorization of a new plant biotechnology derived trait”, focused on biotech traits in large scale commodity crops that had received cultivation approval in two countries and import approvals from at least five countries.
Key findings of the survey included:
Overall Cost
The cost of discovery, development and authorization of a new plant biotechnology trait introduced between 2008 and 2012 is US$136 million
Overall Time to Commercialization
The time from the initiation of a discovery project to commercial launch is 13.1 years on average. This does not include the time required to develop and obtain regulatory approval for stacked trait varieties which are the final product in most crops today.
Number of Years Required to Discover, Develop and Authorize a new Plant Biotech Trait (Mean Values)
Canola |
Corn |
Cotton |
Soybean |
All crops |
|
Number of years from discovery of trait to first commercial sale |
11.7 |
12.0 |
12.7 |
16.3 |
13.1 |
Duration of Each Activity Stage
The time associated with the R&D stage involving registration and regulatory affairs (Stage VII) is increasing from a mean of 44.5 months (3.7 years) for an event introduced before 2002, to the current estimate of 65.5 months (5.5 years). Because various activity stages overlap in real time, these totals do not reflect the actual duration of the overall R&D process described above.
Duration of Each Activity Stage in the Trait R&D Process (mean number of months)
Activity Stage |
Duration for an event sold before 2002 |
Duration for an event introduced between 2008 and 2012 |
Duration to complete each stage in 2011 |
I Early Discovery |
38.0 |
33.9 |
25.8 |
II Late Discovery |
17.3 |
20.0 |
20.9 |
III Construct Optimization |
18.0 |
27.0 |
32.8 |
IV Commercial Event Production & Selection |
24.0 |
30.0 |
34.0 |
V Introgression Breeding & Wide-Area Testing |
40.0 |
37.2 |
42.0 |
VI Regulatory Science |
50.5 |
37.2 |
47.0 |
VII Registration & Regulatory Affairs |
44.5 |
48.8 |
65.5 |
Total Cumulative Time |
232.3 |
234.1 |
268.0 |
Number of Units Evaluated
The trend in the number of units (candidate genes, constructs or genetic events) being subjected to screening in order to develop one trait is increasing from a mean of 1,638 for an event introduced before 2002, to 6,204 for an event introduced between 2008 and 2012. The survey also demonstrated increasing efficiency by the industry with fewer events in the production & selection stage (Stage IV) for the events commercialized in 2008-2012 compared to events introduced before 2002.
Activity Stage |
Event introduced before 2002 |
Event introduced between 2008-2012 |
I Early Discovery |
1,638 |
6,204 |
II Late Discovery |
302 |
4,005 |
III Construct Optimization |
135 |
511 |
IV Commercial Event Production & Selection |
2,853 |
1,302 |
V Introgression Breeding & Wide-Area Testing |
4 |
2 |
VI Regulatory Science |
2 |
1 |
VII Registration & Regulatory Affairs |
1 |
1 |